Market Closed -
Nasdaq
04:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
41.5
USD
|
+4.19%
|
|
+0.95%
|
-30.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,956
|
4,332
|
4,603
|
5,718
|
7,093
|
4,834
|
-
|
-
|
Enterprise Value (EV)
1 |
1,747
|
3,770
|
4,173
|
5,259
|
6,835
|
4,517
|
4,019
|
2,587
|
P/E ratio
|
-6.25
x
|
-12.5
x
|
-5.35
x
|
-8.41
x
|
-13.5
x
|
-43.8
x
|
42.2
x
|
12.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
17.3
x
|
69.2
x
|
75.8
x
|
17.9
x
|
5.89
x
|
4.04
x
|
2.9
x
|
EV / Revenue
|
-
|
15
x
|
62.7
x
|
69.7
x
|
17.2
x
|
5.51
x
|
3.35
x
|
1.55
x
|
EV / EBITDA
|
-6.07
x
|
-17.7
x
|
-7.8
x
|
-8.87
x
|
-13.3
x
|
-53.7
x
|
14.3
x
|
3.43
x
|
EV / FCF
|
-8.21
x
|
-22.7
x
|
-7.4
x
|
-10.2
x
|
-11.5
x
|
-28.7
x
|
18.2
x
|
6.09
x
|
FCF Yield
|
-12.2%
|
-4.4%
|
-13.5%
|
-9.8%
|
-8.71%
|
-3.49%
|
5.5%
|
16.4%
|
Price to Book
|
57.2
x
|
21.3
x
|
23.2
x
|
33.7
x
|
36.5
x
|
25.2
x
|
9.76
x
|
4.48
x
|
Nbr of stocks (in thousands)
|
63,888
|
75,737
|
97,358
|
110,576
|
118,500
|
121,366
|
-
|
-
|
Reference price
2 |
30.62
|
57.20
|
47.28
|
51.71
|
59.86
|
41.50
|
41.50
|
41.50
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/28/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
250.6
|
66.56
|
75.42
|
396.6
|
820.4
|
1,198
|
1,668
|
EBITDA
1 |
-287.8
|
-213.1
|
-534.9
|
-593.1
|
-515.1
|
-84.08
|
281
|
753.4
|
EBIT
1 |
-288
|
-213.7
|
-536.3
|
-594.6
|
-517.1
|
-104.2
|
179.4
|
587.7
|
Operating Margin
|
-
|
-85.27%
|
-805.67%
|
-788.38%
|
-130.39%
|
-12.7%
|
14.97%
|
35.24%
|
Earnings before Tax (EBT)
1 |
-304.7
|
-343
|
-746
|
-651.5
|
-526.5
|
-115.4
|
163.5
|
581
|
Net income
1 |
-304.7
|
-344.9
|
-746.4
|
-652.2
|
-528.6
|
-117
|
132.8
|
435.7
|
Net margin
|
-
|
-137.59%
|
-1,121.27%
|
-864.7%
|
-133.29%
|
-14.26%
|
11.09%
|
26.13%
|
EPS
2 |
-4.900
|
-4.590
|
-8.840
|
-6.150
|
-4.450
|
-0.9469
|
0.9826
|
3.252
|
Free Cash Flow
1 |
-212.8
|
-165.9
|
-564.2
|
-515.3
|
-595.5
|
-157.6
|
221.2
|
424.9
|
FCF margin
|
-
|
-66.19%
|
-847.66%
|
-683.18%
|
-150.16%
|
-19.21%
|
18.46%
|
25.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
78.7%
|
56.39%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
166.47%
|
97.52%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/28/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
60.29
|
14.38
|
16.32
|
22.06
|
22.66
|
44.85
|
94.97
|
110.4
|
146.4
|
172.3
|
192.9
|
216.1
|
239.5
|
250.9
|
270.4
|
EBITDA
1 |
-89.02
|
-128.6
|
-148.2
|
-152.5
|
-163.7
|
-174.7
|
-120
|
-136.6
|
-84.04
|
-61.65
|
-29.77
|
-9.844
|
9.968
|
-
|
-
|
EBIT
1 |
-89.4
|
-129
|
-148.6
|
-152.9
|
-164.1
|
-175.1
|
-120.4
|
-137.1
|
-84.52
|
-62.09
|
-32.11
|
-13.37
|
7.786
|
19.17
|
28.75
|
Operating Margin
|
-148.28%
|
-897%
|
-910.57%
|
-693.41%
|
-723.88%
|
-390.41%
|
-126.82%
|
-124.17%
|
-57.74%
|
-36.03%
|
-16.64%
|
-6.18%
|
3.25%
|
7.64%
|
10.63%
|
Earnings before Tax (EBT)
1 |
-147.7
|
-137.7
|
-155.5
|
-190.8
|
-167.5
|
-177.5
|
-121.8
|
-140
|
-87.15
|
-66.25
|
-35.87
|
-17.01
|
4.15
|
15.22
|
25.32
|
Net income
1 |
-147.9
|
-138.9
|
-156
|
-191.3
|
-166
|
-177.8
|
-122
|
-140.2
|
-88.58
|
-66.42
|
-36.05
|
-17.36
|
2.837
|
14.29
|
24.31
|
Net margin
|
-245.37%
|
-966.1%
|
-955.62%
|
-867.2%
|
-732.43%
|
-396.42%
|
-128.5%
|
-127.03%
|
-60.51%
|
-38.55%
|
-18.69%
|
-8.03%
|
1.18%
|
5.7%
|
8.99%
|
EPS
2 |
-1.610
|
-1.420
|
-1.460
|
-1.750
|
-1.500
|
-1.560
|
-1.020
|
-1.170
|
-0.7300
|
-0.5400
|
-0.2935
|
-0.1426
|
0.0196
|
0.0392
|
0.1422
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/4/22
|
8/8/22
|
11/7/22
|
2/21/23
|
5/4/23
|
7/31/23
|
11/1/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
209
|
562
|
430
|
459
|
258
|
317
|
815
|
2,247
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-213
|
-166
|
-564
|
-515
|
-596
|
-158
|
221
|
425
|
ROE (net income / shareholders' equity)
|
-312%
|
-289%
|
-370%
|
-354%
|
-290%
|
-40.4%
|
28.7%
|
166%
|
ROA (Net income/ Total Assets)
|
-103%
|
-51.1%
|
-81%
|
-79.4%
|
-68.3%
|
-31.9%
|
2.91%
|
257%
|
Assets
1 |
296.4
|
674.9
|
921.2
|
821
|
774.5
|
366.3
|
4,567
|
169.7
|
Book Value Per Share
2 |
0.5400
|
2.690
|
2.040
|
1.530
|
1.640
|
1.650
|
4.250
|
9.250
|
Cash Flow per Share
2 |
-3.390
|
-2.140
|
-6.670
|
-4.840
|
-5.010
|
-0.5200
|
1.320
|
-
|
Capex
1 |
1.69
|
5.42
|
1.1
|
1.52
|
0.77
|
3.57
|
5.6
|
7.11
|
Capex / Sales
|
-
|
2.16%
|
1.66%
|
2.02%
|
0.19%
|
0.44%
|
0.47%
|
0.43%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/28/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
41.5
USD Average target price
77.53
USD Spread / Average Target +86.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -30.67% | 4.83B | | -0.28% | 90.59B | | 0.00% | 38.99B | | -8.52% | 34.09B | | +64.13% | 26.38B | | -17.37% | 15.02B | | -5.99% | 13.17B | | -10.69% | 11.88B | | -47.78% | 10.65B | | +8.09% | 9.25B |
Biopharmaceuticals
|